SynCardia Systems, Inc. manufactures the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage heart failure affecting both sides of the heart (biventricular failure). More than 950 implants account for more than 230 patient years of life.
Similar to a heart transplant, SynCardia’s Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular heart failure and pumps up to 9.5 liters per minute through both ventricles. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Fast Company ranked SynCardia#20 among the World’s 50 Most Innovative Companies “for giving mobility to artificial heart recipients.”
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/10/prweb8914245.htm